Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruzzese

Showing results (681-690 of 766) with videos related to

Pageof 77
Sort By:
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Parapelvic cysts, a distinguishing feature of renal Fabry diseaseAntonio Pisani, Luigi Petruzzelli Annicchiarico, Angela Pellegrino, et al.
The Journal of Biological Chemistry|October 5, 2011
Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analoguesJesse J Chen, Christopher A Tsu, James M Gavin, et al.
BMC Cancer|September 19, 2024
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocolAlfredo Budillon, Alessandra Leone, Eugenia Passaro, et al.
Frontiers in Physiology|March 3, 2020
Imbalance Between Interleukin-1β and Interleukin-1 Receptor Antagonist in Epicardial Adipose Tissue Is Associated With Non ST-Segment Elevation Acute Coronary SyndromeValentina Parisi, Laura Petraglia, Serena Cabaro, et al.
ESMO Open|February 18, 2021
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)C De Angelis, D Bruzzese, A Bernardo, et al.
JACC. Heart Failure|March 6, 2025
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled TrialAlberto Maria Marra, Roberta D'Assante, Mariarosaria De Luca, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 15, 2020
Hepatobiliary scintigraphy and kinetic growth rate predict liver failure after ALPPS: a multi-institutional studyFederico Tomassini, Yves D'Asseler, Michael Linecker, et al.
Molecular Cancer Therapeutics|December 19, 2006
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomibMark J Williamson, Jonathan L Blank, Frank J Bruzzese, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 6, 2024
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cellsAngela Filograna, Stefano De Tito, Matteo Lo Monte, et al.
Pageof 77

Showing results (681-690 of 766) with videos related to

Sort By:
Pageof 77
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Parapelvic cysts, a distinguishing feature of renal Fabry diseaseAntonio Pisani, Luigi Petruzzelli Annicchiarico, Angela Pellegrino, et al.
The Journal of Biological Chemistry|October 5, 2011
Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analoguesJesse J Chen, Christopher A Tsu, James M Gavin, et al.
BMC Cancer|September 19, 2024
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocolAlfredo Budillon, Alessandra Leone, Eugenia Passaro, et al.
Frontiers in Physiology|March 3, 2020
Imbalance Between Interleukin-1β and Interleukin-1 Receptor Antagonist in Epicardial Adipose Tissue Is Associated With Non ST-Segment Elevation Acute Coronary SyndromeValentina Parisi, Laura Petraglia, Serena Cabaro, et al.
ESMO Open|February 18, 2021
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)C De Angelis, D Bruzzese, A Bernardo, et al.
JACC. Heart Failure|March 6, 2025
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled TrialAlberto Maria Marra, Roberta D'Assante, Mariarosaria De Luca, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 15, 2020
Hepatobiliary scintigraphy and kinetic growth rate predict liver failure after ALPPS: a multi-institutional studyFederico Tomassini, Yves D'Asseler, Michael Linecker, et al.
Molecular Cancer Therapeutics|December 19, 2006
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomibMark J Williamson, Jonathan L Blank, Frank J Bruzzese, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 6, 2024
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cellsAngela Filograna, Stefano De Tito, Matteo Lo Monte, et al.
Pageof 77